方法对比

	EDSS：Kurtzke扩展残疾状态量表	MDS-UPDRS：运动障碍协会（Movement Disorder Society）赞助的帕金森病统一评分量表	多发性硬化症功能复合量表	RMI：Rivermead 移动能力指数
领域	神经病学	神经病学	神经病学	神经病学
方法族	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
起源年份	1983	2008	1999	1991
提出者	John F. Kurtzke	Christopher G. Goetz and Movement Disorder Society	Gary Cutter, Richard Rudick, and NMSS Consortium	Frank Collen, Derick Wade, and Rivermead Rehabilitation Centre
类型	Clinician-rated	Clinician-rated	Clinician-administered performance test	Clinician-observed performance test
开创性文献	Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1452.	Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170.	Cutter, G. R., Baier, M. L., Rudick, R. A., et al. (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Multiple Sclerosis, 5(4), 244-250.	Collen, F. M., Wade, D. T., Robb, G. F., Bradshaw, C. M. (1991). The Rivermead Mobility Index: A further development of the Rivermead Motor Assessment. International Disability Studies, 13(2), 50-54.
别名	Expanded Disability Status Scale	UPDRS	MS Functional Composite	Rivermead Mobility Index
相关	4	5	4	5
摘要	The EDSS is the most widely used clinical disability rating scale in multiple sclerosis research and practice. Developed by John Kurtzke in 1983, it provides a 0-10 ordinal scale capturing disease severity across eight neurological functional systems and functional status. The EDSS remains the primary endpoint in MS clinical trials and longitudinal cohort studies, with decades of prognostic and comparative data worldwide.	The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice.	The Multiple Sclerosis Functional Composite (MSFC) is an objective, performance-based assessment of MS-related disability capturing three key functional domains: lower extremity mobility, upper extremity coordination, and cognitive/processing speed. Developed in 1999 by the National MS Society and adopted widely in clinical trials, the MSFC provides quantifiable endpoints complementing the Expanded Disability Status Scale (EDSS). The three-component design addresses EDSS limitations by including cognition and standardizing measurement via timed tasks.	The Rivermead Mobility Index (RMI) is a brief, clinician-observed performance test of basic mobility abilities developed for assessing stroke and neurological rehabilitation outcomes. Published in 1991 by Frank Collen and colleagues at Rivermead Rehabilitation Centre (Oxford, UK), the 15-item index measures bed mobility, sitting/standing balance, transfers, and ambulation. The RMI is widely used in stroke units and rehabilitation settings to track functional recovery and predict discharge outcomes.